SEC Tracker
Get the app

Halozyme Therapeutics HALO

Halozyme Therapeutics reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. No financial statements included in filing

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Halozyme Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. Under Item 2.02, it says it issued a press release that day reporting financial results for the third quarter ended September 30, 2026.
  2. The filing says the press release is attached as Exhibit 99.1 and is furnished under Item 2.02.
  3. It states the release shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
  4. Item 9.01 lists Exhibit 99.1, a press release dated November 5, 2026, and Exhibit 104, the Cover Page Interactive Data File.
  5. The report is signed by Darren Snellgrove, Executive Vice President, Chief Financial Officer, and dated November 5, 2026.

5 of 5 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended September 30, 2026

  • In its 10-Q for the quarter ended September 30, 2026, Halozyme reported revenue of $493.0 million and net income of $247.0 million.
  • That filing shows a gross margin of 83.3% and an operating margin of 59.8%.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the third quarter ended September 30, 2026.1 A copy of the press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report2 and shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended3, (the " Exchange Act " ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

Item 9.01 Financial Statements and Exhibits.

Exhibit No. Description

99.14

Press release dated November 5, 20264

104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)4

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc

(Registrant)

Dated:

November 5, 2026 By:5

/s/ Darren Snellgrove5

Darren Snellgrove5

Executive Vice President, Chief Financial Officer5

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  2. Alkermes ALKS public float $4.7B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.